Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Rebecca L. Elstrom, MD, Leandro Cerchietti, MD, Peter Martin, MD, Richard R. Furman, MD, ShaoNing Yang, MS, Jia Ruan, MD, PhD, Paul Christos, Morton Coleman, MD, Amelyn Rodriguez, Madhu Mazumdar, Ari Melnick, MD, John P. Leonard, MD

Blood (2012) 120 (21): 3706.

https://doi.org/10.1182/blood.V120.21.3706.3706

Published: 2012

Journal Articles

DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.

Maria E Figueroa, MD, Sanne Lugthart, MD, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J. Christos, PhD, Elizabeth Schifano, Jim Booth, Lucy Skrabanek, Fabien Campagne, Madhu Mazumdar, PhD, John Greally, MB, PhD, Peter Valk, Bob Lowenberg, MD, PhD, Ruud Delwel, PhD, Ari Melnick

Blood (2009) 114 (22): 707.

https://doi.org/10.1182/blood.V114.22.707.707

Published: 2009

Journal Articles

Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML)

Maria E Figueroa, MD, Sanne Lugthart, MD, Yushan Li, Claudia Erpelinck-Verschueren, Paul J Christos, MS, MPH, Madhu Mazumdar, PhD, Bob Löwenberg, MD, PhD, John Greally, MB, PhD, Peter JM Valk, PhD, Ruud Delwel, PhD, Ari Melnick, MD

Blood (2008) 112 (11): 756.

https://doi.org/10.1182/blood.V112.11.756.756

Published: 2008

Journal Articles

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Blood (2008) 111 (3): 1101–1109.

https://doi.org/10.1182/blood-2007-05-090258

Published: 2008

Includes: Supplemental data

Journal Articles

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Y. Lynn Wang, PhD, Richard Lent, MD, Paul J. Christos, MPH, Joong W. Lee, PhD, Yashpal P. Agrawal, MD/PhD, Susan Matthews, PhD, Scott Ely, MD, Madhu Mazumdar, PhD, Ethel Cesarman, MD, April Rambo, RN, John P. Leonard, MD, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 2737.

https://doi.org/10.1182/blood.V110.11.2737.2737

Published: 2007

Journal Articles

Defective Transport Is a Common Mechanism of Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia and Is Associated With Decreased Reduced Folate Carrier Expression

Richard Gorlick, Erdem Goker, Tanya Trippett, Peter Steinherz, Yaroslav Elisseyeff, Madhu Mazumdar, Wayne F. Flintoff, Joseph R. Bertino

Blood (1997) 89 (3): 1013–1018.

https://doi.org/10.1182/blood.V89.3.1013

Published: 1997

NARROW

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.

Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML)

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Defective Transport Is a Common Mechanism of Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia and Is Associated With Decreased Reduced Folate Carrier Expression

Email alerts

ASH Publications

American Society of Hematology

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.

Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML)

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.

Defective Transport Is a Common Mechanism of Acquired Methotrexate Resistance in Acute Lymphocytic Leukemia and Is Associated With Decreased Reduced Folate Carrier Expression

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only